LSD-Quinoline

LSD-Quinoline
Clinical data
Drug classSerotonin receptor agonist; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • (7aR,10R)-N,N-diethyl-8-methyl-7a,8,9,10-tetrahydro-7H-quinolino[7,6,5-de]quinoline-10-carboxamide
Chemical and physical data
FormulaC21H25N3O
Molar mass335.451 g·mol−1
3D model (JSmol)
  • CCN(C([C@@H](C1)C=C2C3=C4C(C[C@@]2([H])N1C)=CC=NC4=CC=C3)=O)CC
  • InChI=1S/C21H25N3O/c1-4-24(5-2)21(25)15-11-17-16-7-6-8-18-20(16)14(9-10-22-18)12-19(17)23(3)13-15/h6-11,15,19H,4-5,12-13H2,1-3H3/t15-,19-/m1/s1
  • Key:JKMAOHMIUIWQHW-DNVCBOLYSA-N

LSD-Quinoline is a serotonin receptor modulator related to the lysergamide family and to lysergic acid diethylamide (LSD), first synthesised by David E. Olson and colleagues. It acts as a moderately selective serotonin receptor agonist, primarily at the serotonin 5-HT2A receptor, though its activity at other subtypes such as the 5-HT2B and 5-HT2C receptors, and at other targets of LSD such as dopamine receptors, has not been published. It was developed in the course of resarch into non-hallucinogenic psychoplastogens, and is described as having around 24x lower potency than LSD and with "reduced hallucinogenic potential", though this would suggest it may still be of a similar potency to many psychedelic tryptamine derivatives. It has been researched for therapeutic applications including as a potential antidepressant. LSD-Quinoline was first described in the scientific literature by 2026.

See also